Brokers Issue Forecasts for Medicus Pharma FY2029 Earnings

Medicus Pharma Ltd (NASDAQ:MDCX) – Stock analysts at Brookline Capital Management increased their FY2029 earnings estimates for shares of Medicus Pharma in a research note issued on Tuesday, November 18th. Brookline Capital Management analyst K. Raja now expects that the company will post earnings of $1.20 per share for the year, up from their prior forecast of $1.06. The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27).

MDCX has been the topic of several other reports. D. Boral Capital reiterated a “buy” rating and set a $27.00 price target on shares of Medicus Pharma in a research report on Thursday, November 13th. Zacks Research raised shares of Medicus Pharma to a “hold” rating in a research note on Monday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.50.

Medicus Pharma Stock Performance

NASDAQ:MDCX opened at $2.14 on Wednesday. The business’s fifty day moving average is $2.42 and its 200 day moving average is $2.94. The firm has a market cap of $47.14 million and a price-to-earnings ratio of -1.00. Medicus Pharma has a 52-week low of $1.79 and a 52-week high of $8.94.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MDCX. Jane Street Group LLC bought a new stake in Medicus Pharma during the second quarter valued at approximately $41,000. Osaic Holdings Inc. raised its position in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after buying an additional 9,000 shares in the last quarter. Brave Asset Management Inc. purchased a new stake in Medicus Pharma during the third quarter valued at about $46,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Medicus Pharma during the 3rd quarter valued at about $59,000. Finally, May Hill Capital LLC bought a new stake in Medicus Pharma in the 2nd quarter worth approximately $107,000.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.